BrianLeyland-JonesMD
Oncology • Sioux Falls, SDProfessor, Hematology and Medical Oncology, Emory University School of Medicine
Dr. Leyland-Jones is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1000 E 23rd St
Ste 200
Sioux Falls, SD 57105Phone+1 605-322-4673Fax+1 605-322-3020
Education & Training
University of London Faculty of MedicineClass of 1973
Certifications & Licensure
ND State Medical License 2013 - 2026
GA State Medical License 2007 - 2025
NY State Medical License 1980 - 2025
SD State Medical License Active through 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Combination Chemotherapy in Treating Patients With Colorectal Cancer Start of enrollment: 2000 Jul 01
- Studying Tumor Samples From Women Who Have Undergone Chemotherapy for Breast Cancer Start of enrollment: 2008 Jun 17
- Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Advanced Gynecologic Malignancies and Breast Start of enrollment: 2017 Jul 17
- Join now to see all
Publications & Presentations
PubMed
- 46 citationsMolecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve study.Jason K. Sicklick, Shumei Kato, Ryosuke Okamura, Hitendra Patel, Mina Nikanjam
Genome Medicine. 2021-10-04 - 52 citationsAssessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clini...W. Fraser Symmans, Christina Yau, Yunn Yi Chen, Ronald Balassanian, Molly Klein
JAMA Oncology. 2021-09-16 - 3 citationsIntra- and Interlaboratory Reproducibility of the Sensitivity to Endocrine Therapy Assay for Stage II/III Breast Cancer.Veerle Bossuyt, Rosanna Lau, Brandon Young, John G. Howe, Fengmin Zhao
Clinical Chemistry. 2021-09-01
Press Mentions
At Initial Cancer Diagnosis, a Deeply Personalized AssessmentOctober 13th, 2021
Grant Support
- Towards Identification Of Prognostic Gene Sets In Breast Cancer: The E2197 TrialNational Cancer Institute2010–2011
- Senior LeadershipNational Cancer Institute2009–2011
- Program Planning &EvaluationNational Cancer Institute2009–2011
- Developmental FundsNational Cancer Institute2009–2011
- Data Safety Monitoring PLANNational Cancer Institute2009–2011
- Clinical Trials- Protocol SpecificNational Cancer Institute2009–2011
- Clinical Trials - Protocol Review Monitoring SystemNational Cancer Institute2009–2011
- Prognostic And Predictive Gene Sets In Her2-Positive Breast Cancer:The Hera TrialNational Cancer Institute2009–2010
- Emory Winship Cancer Institute Cancer Center Support GrantNational Cancer Institute2009
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
